Buy Januvia (Sitagliptin) 100 mg Merck

Taking DPP-4 inhibitors is associated with a risk of developing acute pancreatitis. Acute pancreatitis, such as necrotic or hemorrhagic pancreatitis and / or death, has been reported (see Adverse Reactions Section). Patients should be informed about a characteristic symptom of acute pancreatitis - persistent, severe abdominal pain. After discontinuation of sitagliptin (with or without maintenance therapy), the symptoms of pancreatitis disappeared. In case of suspected pancreatitis, the use of Januvia should be discontinued; if acute pancreatitis is confirmed, the drug should not be restored. Patients with a history of pancreatitis should be careful.

hypoglycemia

During clinical trials of the use of Januvia as a monotherapy or as part of combination therapy with metformin or a PPARγ agonist (thiazolidinedione), the incidence of hypoglycemia was similar to that with placebo. As with other hypoglycemic drugs, when taking Januvia, episodes of hypoglycemia were observed when it was used as part of combination therapy with insulin or with a sulfonylurea drug. Therefore, to reduce the risk of hypoglycemia, a lower dose of sulfonylurea or insulin should be used (see Section "Adverse Reactions").

renal failure

The drug Januvia is excreted by the kidneys. To achieve a plasma concentration of Januvia drug similar to that in patients with normal renal function, it is recommended to use lower doses of the drug for patients with GFR <45 ml / min, as well as for patients with TSHN requiring hemodialysis or peritoneal dialysis (see Sections “method of application and doses "," Pharmacological properties ").

buy januvia 50 mg
januvia 50 mg tablet price
buy januvia 100 mg
buy januvia 100 mg online uk
januvia 100 mg tablet price
januvia 100mg price
januvia pills for sale
januvia 100 mg oral tablet
januvia 100 mg price in usa

Considering the use of sitagliptin in combination with other antidiabetic drugs, you should check the features of its use in patients with renal failure.

Hypersensitivity reactions

In the post-marketing period of the use of the drug Januvia, serious allergic reactions have been reported. These reactions include anaphylaxis, angioedema, and exfoliative skin diseases, including Stevens-Johnson syndrome (see Adverse Reactions). These reactions occurred during the first 3 months after starting treatment with Januvia, and sometimes ˗ after applying the first dose. In case of suspicion of an allergic reaction, the use of Januvia should be discontinued, other potential causes of the particular phenomenon should be assessed, and alternative treatment for diabetes should be determined.

bullous pemphigoid

During post-marketing observation in patients with the use of DPP-4 inhibitors, including sitagliptin, cases of bullous Pemphigoid have been reported. If there is a suspicion of bullous pemphigoid, taking Januvia should be discontinued.

Use during pregnancy or lactation
Controlled clinical studies of the drug Januvia with the participation of pregnant women have not been carried out, therefore it is not recommended for use during pregnancy.

There is no data on the excretion of sitagliptin into breast milk, so the drug is not prescribed during lactation.

Animal studies have shown reproductive toxicity when using the drug in large doses.

Animal studies do not indicate a possible effect of sitagliptin treatment on male and female fertility. The potential risk to humans is unknown.

No human studies are available.

The ability to influence the reaction rate when driving vehicles or other mechanisms
When driving motor vehicles or other mechanisms, special caution is recommended, given the possibility of developing adverse reactions from the nervous system (dizziness, drowsiness).

Patients should be warned about the risk of hypoglycemia when using Januvia as part of a combination treatment.

Januvia 100 mg Merck